Release Date: 17-Jul-2024
IMM2902 is a first-in-class bispecific antibody-receptor fusion protein produced by ImmuneOnco Biopharmaceuticals in Shanghai that targets human CD47 and HER2. It is the company’s third CD47-based novel medicine concept to reach clinical testing, and it was built on their mAb-Trap technology platform. With its distinct and advantageous mechanism of action, IMM2902 is at the forefront of improving treatment results in advanced solid malignancies.
IMM2902’s bispecificity contributes to its mechanism of action. IMM2902 not only blocks the ‘don’t eat me’ signal triggered downstream of the CD47/SIRP cascade, but it also triggers strong antibody-dependent cell-mediated cytotoxicity and antibody-dependent cellular phagocytosis activity with a specifically engineered IgG1 Fc fragment. Most significantly, IMM2902 promotes HER2 degradation in tumor tissues. Despite its high affinity for CD47, IMM2902 does not bind to CD47 on the erythrocyte membrane; thus, unlike traditional CD47-directed monoclonal antibodies, IMM2902 has no effect on red blood cells.
In preclinical trials, IMM2902 displayed substantial anticancer activity in a number of breast and gastric tumor models, among which were with HER2-low expression and trastuzumab resistance. ImmuneOnco is currently evaluating IMM2902 in advanced HER2-positive and HER2-low expressing solid tumors such as breast cancer, gastric cancer, non-small cell lung cancer, biliary tract cancer, and cholangiocarcinoma in the US and China. While the findings of the US trial are still pending, the Chinese trial found IMM2902 to be safe and well tolerated up to 2.0 mg/kg. Dosing for higher dose level cohorts is still ongoing.
As clinical trial findings for IMM2902 become available, drug regulatory bodies and organizations interested in pharmacological innovation are recognizing its therapeutic promise in these HER2-expressing malignancies. The FDA granted IMM2902 Fast Track Designation (FTD) for the treatment of breast cancer in July 2022, which was a significant affirmation for IMM2902. The candidate also earned the ‘Annual Drug Innovation Pioneering Award’ at the Securities Times’ Second Drug Innovation Award Ceremony in August 2022, adding another milestone to its name.
In conclusion, the development of IMM2902 represents a huge step forward in the pursuit of precision cancer treatment. IMM2902 is a promising treatment candidate since it targets the unique combination of CD47 and HER2. As clinical trial findings become available, the ability of IMM2902 to demonstrate relevant efficacy and safety profiles may pave the path for its inclusion in the expanding landscape of cancer medicines. IMM2902 has the ability to not only address the complexities of HER2-positive tumors, but also to broaden its applications across a range of solid cancers.
For Clinical Trials Information Contact